Clinical Advisor21h
High Dose Ocrelizumab Shows No Added Benefit for Relapsing MS Patients
The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.
BioSpace1d
Aldeyra Shares Crash as Dry Eye Drug Gets Second Rejection from FDA
The FDA has asked for another well-controlled trial to establish the efficacy of reproxalap in dry eye disease.
Stocktwits on MSN2d
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic
Shares of Aldeyra Therapeutics, Inc. (ALDX) slumped nearly 71% on Thursday morning after it said that the U.S. Food and Drug ...
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
Medscape2d
Two Oral TYK2 Inhibitors Enter Phase 3 Trials for Plaque Psoriasis on Basis of Phase 2 Promise
Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...
Roche’s Top Drug’s New High-Dose Version Fails in Study
Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...